Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs

Bing-rong Zheng; Jian-ping Shen; Hai-feng Zhuang; Sheng-yun Lin; Yi-ping Shen; Yu-hong Zhou

doi:10.1007/s11655-009-0141-9

Your Location：

Home >

Browse articles >

Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs

OriginalPaper | Updated：2021-08-27

- Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs
- Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs
- 中国结合医学杂志（英文版） 2009年15卷第2期页码：145-148
- Affiliations：
  
  Department of Hematology, First Clinical Medical College Affiliated to Zhejiang University of Traditional Chinese Medicine,Hangzhou,China
- Author bio：
- Funds：
  
  Supported by the Key Program of the Governmental Office of Sciences and Technology of Zhejiang Provincial (No. 2006c23039)
- DOI：10.1007/s11655-009-0141-9
  中图分类号：
- 纸质出版日期：2009，
  
  网络出版日期：2009-4-29，
Scan for full text
Zheng, Br., Shen, Jp., Zhuang, Hf. et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs., Chin. J. Integr. Med. 15, 145–148 (2009). https://doi.org/10.1007/s11655-009-0141-9

Bing-rong Zheng, Jian-ping Shen, Hai-feng Zhuang, et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs[J]. Chinese Journal of Integrative Medicine, 2009,15(2):145-148.
Zheng, Br., Shen, Jp., Zhuang, Hf. et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs., Chin. J. Integr. Med. 15, 145–148 (2009). https://doi.org/10.1007/s11655-009-0141-9 DOI：

Bing-rong Zheng, Jian-ping Shen, Hai-feng Zhuang, et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs[J]. Chinese Journal of Integrative Medicine, 2009,15(2):145-148. DOI： 10.1007/s11655-009-0141-9.

摘要

To study the therapeutic effect of combined therapy with Chinese drugs and immuno-suppressors

mainly anti-lymphocyte globulin/anti-thymus globulin (ALG/ATG)

for the treatment of severe aplastic anemia (SAA)

the efficacy associated factors and adverse effects as well. A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A

androgen

hematopoietic growth factor

etc. Of the 57 patients followed-up

26 (45.6%) were basically cured

15 (26.3%) remitted

and 8 (14.0%) improved markedly

the total effective rate being 85.9%. By separately comparing with a single item of clinical data

it was shown that the therapeutic effectiveness was correlated

to a certain extent

with age

illness duration

neutrophil count

and bone marrow proliferation in patients before treatment

as well as with infection that occurred in the follow-up period. It was obviously higher in patients with peripheral neutrophil count > 0.5 × 10 109/L (P<0.05). Various degrees of serum sickness-like reactions occurred in the treatment of 36 patients

including fever in 36 (63.2%)

skin rash in 8 (14.0%)

and musculoskeletal pain in 5 (8.8%). The therapeutic effect of combined therapy with Chinese drugs and ALG/ATG in treating SAA could be affirmed

showing some superiority as compared with Western medicine alone. The patients’ age

duration of illness

neutrophil count

and bone marrow proliferation before treatment

and degree of infection that occurred could affect the therapeutic efficacy to a certain extent. Adverse reactions resulting from the combined therapy are less

showing the toxicity reducing and effect enhancing action of Chinese drugs.

Abstract

To study the therapeutic effect of combined therapy with Chinese drugs and immuno-suppressors

mainly anti-lymphocyte globulin/anti-thymus globulin (ALG/ATG)

for the treatment of severe aplastic anemia (SAA)

the efficacy associated factors and adverse effects as well. A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A

androgen

hematopoietic growth factor

etc. Of the 57 patients followed-up

26 (45.6%) were basically cured

15 (26.3%) remitted

and 8 (14.0%) improved markedly

the total effective rate being 85.9%. By separately comparing with a single item of clinical data

it was shown that the therapeutic effectiveness was correlated

to a certain extent

with age

illness duration

neutrophil count

and bone marrow proliferation in patients before treatment

including fever in 36 (63.2%)

skin rash in 8 (14.0%)

and musculoskeletal pain in 5 (8.8%). The therapeutic effect of combined therapy with Chinese drugs and ALG/ATG in treating SAA could be affirmed

showing some superiority as compared with Western medicine alone. The patients’ age

duration of illness

neutrophil count

and bone marrow proliferation before treatment

and degree of infection that occurred could affect the therapeutic efficacy to a certain extent. Adverse reactions resulting from the combined therapy are less

showing the toxicity reducing and effect enhancing action of Chinese drugs.

关键词

anti-lymphocyte globulin/anti-thymus globulinChinese Drugaplastic anemia

Keywords

anti-lymphocyte globulin/anti-thymus globulinChinese Drugaplastic anemia

references

He GS, Shao ZH. Current situation of immune inhibitory treatment on aplastic anemia. Chin J Hematol (Chin) 2002;23:611–613.

Chu YL, Hao YS, Bian SK. Clinical study of antithymocyte globulin in the treatment of children aplastic anemia. Chin J Hematol (Chin) 1986;7:198.

Zhang ZN, ed. Norm for diagnosis and efficacy assessment of hematopathy. Beijing: Science Press; 2008:19–23.

Ying XM, Wang YP. Adverse reaction of antithymocyte globulin in the treatment of 28 cases children aplastic anemia. J China Pediatr Blood (Chin) 2000;5:198–201.

Yu F, Tang SQ, Wang JW. Therapeutic effect of antithymocyte/antilymphocyte globulin on severe aplastic anemia and therapy-related complications. Chin J Contemporary Pediatr (Chin) 2006;8:479–481.

Bacigalupo A, Brand R, Oneto R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000;37:69–80.

Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931–1934.

Rosenfeld S, Follmann D, Nunezo, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130–1135.

Shao ZH, Yuan Y. Immune pathogenesis and therapy for aplastic anemia. Chin J Pract Intern Med (Chin) 2006;26:252–255.

FULL TEXT LINK

More>

浏览量

370

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Bone marrow angiogenesis in patients presenting with differential Chinese medicine syndrome: Correlation with the clinico-pathological features of aplastic anemia

Effect of Chinese drugs combining with chemotherapy on quality of life in 146 children with solid tumor

Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China

Clinical efficacy and safety of Gubitong Recipe (骨痹通方) in treating osteoarthritis of knee joint

Current status and progress of study on perioperative period